A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types
NCT ID: NCT05907447
Last Updated: 2023-06-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
10000 participants
OBSERVATIONAL
2023-07-01
2024-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Retrospective Study on Extranodal DLBCL
NCT06549361
A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
NCT05444322
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
NCT06651853
A Real-World Study on Extranodal Lymphoma
NCT06573099
Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.
NCT05821192
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No interventions need to be specified for this study
No interventions need to be specified for this study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients newly diagnosed with non-Hodgkin lymphoma with extranodal involvement, whether it is primary, secondary, or cannot be determined; Or patients newly diagnosed with non-Hodgkin lymphoma of rare pathological types, including IVLBCL, SMZL, ALCL, AITL, MALTL.
3. Patients who have received systematic clinical treatment.
4. Patients with measurable lesions, at least containing one effective evaluation of efficacy.
Exclusion Criteria
2. Patients who cannot obtain effective evaluation data of efficacy.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nanfang Hospital, Southern Medical University
OTHER
Fujian Medical University Union Hospital
OTHER
Peking University Third Hospital
OTHER
Peking University People's Hospital
OTHER
Peking Union Medical College Hospital
OTHER
Beijing Hospital
OTHER_GOV
The Second Affiliated Hospital of Dalian Medical University
OTHER
The First Affiliated Hospital of Guangzhou Medical University
OTHER
Henan Provincial People's Hospital
OTHER
Hunan Cancer Hospital
OTHER
Henan Cancer Hospital
OTHER_GOV
The First Hospital of Jilin University
OTHER
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
OTHER
Affiliated Hospital of Nantong University
OTHER
The First Affiliated Hospital of Xiamen University
OTHER
Shandong Provincial Hospital
OTHER_GOV
Shanxi Province Cancer Hospital
OTHER
RenJi Hospital
OTHER
Beijing Friendship Hospital
OTHER
West China Hospital
OTHER
The First Affiliated Hospital of Soochow University
OTHER
Tongji Hospital
OTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Sun Yat-sen University
OTHER
Chongqing University Cancer Hospital
OTHER
Anhui Provincial Cancer Hospital
OTHER
The General Hospital of Northern Theater Command
OTHER
Qilu Hospital of Shandong University
OTHER
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
OTHER
The Affiliated Hospital Of Guizhou Medical University
OTHER
Wuhan TongJi Hospital
OTHER
General Hospital of Ningxia Medical University
OTHER
The First Affiliated Hospital of Nanchang University
OTHER
The First Affiliated Hospital with Nanjing Medical University
OTHER
Anshan Central Hospital
OTHER
Hainan Cancer Hospital
OTHER
Fifth Affiliated Hospital of Guangzhou Medical University
OTHER
The First Affiliated Hospital of Anhui Medical University
OTHER
The Affiliated Hospital of Xuzhou Medical University
OTHER
First Affiliated Hospital of Harbin Medical University
OTHER
Zhujiang Hospital
OTHER
Ruijin Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhao Weili
Prof.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EXPECT-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.